Literature DB >> 30617138

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Roser Pinyol1, Daniela Sia2, Josep M Llovet3,2,4.   

Abstract

Next-generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of these data is needed to customize immunotherapy in advanced HCC.See related article by Harding et al., p. 2116. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30617138      PMCID： PMC6445700          DOI： 10.1158/1078-0432.CCR-18-3778

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

Authors:  Daniela Sia; Yang Jiao; Iris Martinez-Quetglas; Olga Kuchuk; Carlos Villacorta-Martin; Manuel Castro de Moura; Juan Putra; Genis Camprecios; Laia Bassaganyas; Nicholas Akers; Bojan Losic; Samuel Waxman; Swan N Thung; Vincenzo Mazzaferro; Manel Esteller; Scott L Friedman; Myron Schwartz; Augusto Villanueva; Josep M Llovet
Journal:  Gastroenterology       Date:  2017-06-15       Impact factor: 22.682

4.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

5.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

6.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Authors:  Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; Subhiksha Nandakumar; Joshua Armenia; Danny N Khalil; Melanie Albano; Michele Ly; Jinru Shia; Jaclyn F Hechtman; Ritika Kundra; Imane El Dika; Richard K Do; Yichao Sun; T Peter Kingham; Michael I D'Angelica; Michael F Berger; David M Hyman; William Jarnagin; David S Klimstra; Yelena Y Janjigian; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-29       Impact factor: 12.531

7.  Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Authors:  Roser Pinyol; Robert Montal; Laia Bassaganyas; Daniela Sia; Tadatoshi Takayama; Gar-Yang Chau; Vincenzo Mazzaferro; Sasan Roayaie; Han Chu Lee; Norihiro Kokudo; Zhongyang Zhang; Sara Torrecilla; Agrin Moeini; Leonardo Rodriguez-Carunchio; Edward Gane; Chris Verslype; Adina Emilia Croitoru; Umberto Cillo; Manuel de la Mata; Luigi Lupo; Simone Strasser; Joong-Won Park; Jordi Camps; Manel Solé; Swan N Thung; Augusto Villanueva; Carol Pena; Gerold Meinhardt; Jordi Bruix; Josep M Llovet
Journal:  Gut       Date:  2018-08-14       Impact factor: 23.059
  7 in total
  61 in total

1.  Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-10-26       Impact factor: 11.740

2.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-15       Impact factor: 11.740

Review 3.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 4.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

5.  Berberine Represses β-Catenin Translation Involving 4E-BPs in Hepatocellular Carcinoma Cells.

Authors:  Kanchan Vishnoi; Rong Ke; Karan S Saini; Navin Viswakarma; Rakesh Sathish Nair; Subhasis Das; Zhengjia Chen; Ajay Rana; Basabi Rana
Journal:  Mol Pharmacol       Date:  2020-10-31       Impact factor: 4.436

Review 6.  Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.

Authors:  Taiji Yamazoe; Taizo Mori; Sachiyo Yoshio; Tatsuya Kanto
Journal:  Glob Health Med       Date:  2020-10-31

7.  Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.

Authors:  Zhi-Qiang Hu; Hao-Yang Xin; Chu-Bin Luo; Jia Li; Zheng-Jun Zhou; Ji-Xue Zou; Shao-Lai Zhou
Journal:  Cancer Immunol Immunother       Date:  2020-08-06       Impact factor: 6.968

Review 8.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

9.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

10.  An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.

Authors:  Agrin Moeini; Sara Torrecilla; Victoria Tovar; Carla Montironi; Carmen Andreu-Oller; Judit Peix; Mónica Higuera; Dominik Pfister; Pierluigi Ramadori; Roser Pinyol; Manel Solé; Mathias Heikenwälder; Scott L Friedman; Daniela Sia; Josep M Llovet
Journal:  Gastroenterology       Date:  2019-07-22       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.